CardioAcademic

Comunidad especializada en Cardiología, con el objetivo de fomentar la educación continúa a través del trabajo y participación en conjunto.

[JACC Journals @JACCJournals]

State-of-the-art review in #JACCHF: Alterations in skeletal muscle (SkM) structure & metabolism are key contributors to #Exercise intolerance in #HeartFailure. Exercise training + novel pharmacotherapies targeting SkM dysfunction are emerging to treat it.

https://t.co/gHQxt4xaG5

[Circulation @CircAHA]

Full article: https://t.co/NtVLOiJaWa
@AHAScience
Authors: @ZMotovska @MarcoGuglielmo @DLBHATTMD

[Circulation @CircAHA]

Just Published at #ScientificSessions26: Multimodality Cardiac Imaging Substudy of the DAPT-SHOCK-AMI Randomized Trial: Echocardiographic and Cardiac Magnetic Resonance Assessment of Cangrelor versus Crushed Ticagrelor in Cardiogenic Shock Complicating Acute Myocardial Infarc...\

[AHA Science @AHAScience]

Cardiovascular-kidney-metabolic (CKM) health is a major focus at #ScientificSessions26.

🎥 Science Communicator @HeartDocSadiya, MD, MSc, FAHA shares the many ways attendees can the latest science in CKM health through learning labs, symposia and focused sessions.

[AHA Science @AHAScience]

🎥 @MoradiShayan, MS, PhD, talks through some of the valuable early career programming at #ScientificSessions26, covering topics such as getting involved with the American Heart Association, strengthening grant and manuscript writing skills, and building a roadmap for future success.

[AHA Science @AHAScience]

Join us at #ScientificSessions26 for The Ups and Downs of Sex Hormones: Critical Windows for Cardiovascular Health in Girls and Women.

Join moderator Jennifer Ashton, MD, MS, FACOG, and a panel of speakers to explore key connections between hormones and cardiovascular health across the lifespan.

📅 Nov. 7 | 3:15-4:30 PM CT
📍 S105D

[AHA Science @AHAScience]

ZEUS results presented at #ScientificSessions26.

Lowering interleukin-6 levels with ziltivekimab did not lower the risk of cardiovascular events in patients with ASCVD, CKD, and cardiovascular inflammation compared to placebo.

[AHA Science @AHAScience]

Lp(a) HORIZON, presented at #ScientificSessions26 showed Pelacarsen substantially lowered lipoprotein(a) but did not reduce risk of MACE compared to placebo in patients on guideline-directed medical therapy for secondary prevention of CVD.

More from @VietHeartPA 👇

[AHA Science @AHAScience]

@MoradiShayan discusses late breaking science results from ZEUS at #ScientificSessions26.

[AHA Science @AHAScience]

STREAM Results presented at #ScientificSessions26

Statin discontinuation was noninferior to continuation for a composite of major cardiovascular events and death from any cause at 2 years.

[AHA Science @AHAScience]

@DrDamluji discusses late breaking science results from ZEUS at #ScientificSessions26.

[AHA Science @AHAScience]

@AnastasiaSMihai discusses late breaking science from OPTIMAL-STROKE at #ScientificSessions26. 🎥

[AHA Science @AHAScience]

@emilyswlau discusses late breaking science from Lp(a) HORIZON at #ScientificSessions26. 🎥

[AHA Science @AHAScience]

Yoga-CaRe HR results presented at #ScientificSessions26

Yoga-based cardiac rehabilitation improved quality of life, increased 6-minute walk distance, and improved quality-adjusted utility value at 3 months compared with enhanced standard care, with differences persisting through 24 months. The intervention did not significantly reduce the composite clinical endpoint of death, repeat hospitalization, or stroke.

[NEJM @NEJM]

Presented at #ScientificSessions26:

In older adults with at least two chronic conditions and no known atherosclerotic cardiovascular disease, statin discontinuation was noninferior to continuation for a composite of myocardial infarction, stroke, or death at 2 years. Full STREAM trial results: https://t.co/e0YZJbXGg2

@AHAScience

[Peder L. Myhre MD, PhD @pmyhre]

ZEUS unfortunately completely neutral. Not even a signal for CV events.😳

[C. Michael Gibson MD @CMichaelGibson]

Dr. Behnood Bikdeli and Dr. C. Michael Gibson discuss the HIPRO extension study: 1-year treatment with low-intensity apixaban 2.5 mg twice daily reduced the overall 2-year risk of VTE recurrence compared with placebo in patients with enduring risk factors, with loss of benefit within the period without active treatment.

Watch video here: https://t.co/qLRhSualeP

[C. Michael Gibson MD @CMichaelGibson]

CHIP-BCIS3 trial secondary analysis: Microaxial flow pump use during complex PCI was associated with a higher risk of cardiovascular death, which was only partially mediated by procedure-related myocardial injury.

Download slides here: https://t.co/8rvBSEzxm7

[Women As One @WomenAs1]

Women represented just 37.5% of patients undergoing intervention for primary mitral regurgitation & had higher long-term mortality & major cardiovascular events.

This raises important questions about how and when women are diagnosed & treated.

https://t.co/sf7oQCjL06

[Eric Topol @EricTopol]

Today #AHA26 and @NEJM the 2 big trials of secondary prevention of heart disease with an IL-6 antibody and Lp(a) antisense oligonucleotide. No beneficial effect, overall and across all subgroups
https://t.co/cvsnrXuhHI
https://t.co/hVFA1eAQQC